Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects

NCT02418650 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: ODM-201 300 mg tablet
DRUG: intravenous14C-ODM-201
DRUG: 300 mg 14C-ODM-201 oral solution

Sponsor

Orion Corporation, Orion Pharma

Collaborators

[object Object]